Profile data is unavailable for this security.
About the company
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
- Revenue in USD (TTM)0.00
- Net income in USD-84.61m
- Incorporated2018
- Employees51.00
- LocationAerovate Therapeutics Inc930 Winter Street, Suite M-500WALTHAM 02451United StatesUSA
- Phone+1 (617) 443-2400
- Fax+1 (302) 655-5049
- Websitehttps://www.aerovatetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc | 631.56k | -32.50m | 73.81m | 25.00 | -- | 0.968 | -- | 116.87 | -0.4598 | -0.4598 | 0.0089 | 1.07 | 0.0056 | -- | -- | 15,789.00 | -28.55 | -20.78 | -31.34 | -23.27 | -- | -- | -5,146.15 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 74.17m | 12.00 | -- | 9.02 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.56m | 74.56m | 25.00 | -- | 3.39 | -- | -- | -1.17 | -1.17 | 0.00 | 0.5975 | 0.00 | -- | -- | 0.00 | -73.98 | -51.63 | -98.74 | -59.00 | -- | -- | -- | -- | -- | -19.13 | 0.5286 | -- | -- | -- | -5.11 | -- | -- | -- |
| VolitionRX Ltd | 1.29m | -29.87m | 74.60m | 110.00 | -- | -- | -- | 58.02 | -0.3623 | -0.3623 | 0.0155 | -0.2328 | 0.0837 | -- | 7.41 | 11,689.36 | -196.61 | -111.92 | -- | -196.20 | -- | -- | -2,348.71 | -10,793.31 | -- | -104.15 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Armata Pharmaceuticals Inc | 5.47m | -41.36m | 75.62m | 66.00 | -- | -- | -- | 13.83 | -1.24 | -1.24 | 0.1312 | -1.41 | 0.0518 | -- | 1.02 | 82,833.34 | -39.21 | -59.78 | -116.66 | -72.70 | -- | -- | -756.59 | -1,113.72 | -- | -- | 1.90 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Aerovate Therapeutics Inc | 0.00 | -84.61m | 76.79m | 51.00 | -- | 0.954 | -- | -- | -2.99 | -2.99 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -72.99 | -- | -81.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 76.79m | 50.00 | -- | 0.5957 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -17.78m | 77.64m | 10.00 | -- | 27.76 | -- | -- | -0.8864 | -0.8864 | 0.00 | 0.0807 | 0.00 | -- | -- | 0.00 | -149.60 | -- | -225.38 | -- | -- | -- | -- | -- | -- | -- | 0.0403 | -- | -- | -- | -272.15 | -- | -- | -- |
| Chimerix Inc | 159.00k | -83.59m | 79.14m | 72.00 | -- | 0.5829 | -- | 497.76 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| CervoMed Inc | 10.07m | -11.95m | 79.57m | 8.00 | -- | 1.74 | -- | 7.90 | -1.60 | -1.60 | 1.35 | 5.53 | 0.3305 | -- | -- | 1,258,319.00 | -39.22 | -53.67 | -43.28 | -58.89 | -- | -- | -118.68 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.26m | 79.63m | 32.00 | -- | 1.77 | -- | -- | -1.25 | -1.25 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -50.27 | -42.72 | -52.16 | -46.06 | -- | -- | -- | -- | -- | -- | 0.249 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Clearside Biomedical Inc | 7.70m | -31.88m | 79.64m | 30.00 | -- | -- | -- | 10.34 | -0.4503 | -0.4503 | 0.1094 | -0.4654 | 0.2423 | -- | 9.23 | 256,766.70 | -100.27 | -63.57 | -122.24 | -81.77 | 97.01 | -- | -413.83 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 79.69m | 143.00 | -- | 0.3767 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -32.28m | 79.77m | 16.00 | -- | 5.02 | -- | -- | -0.7113 | -0.7113 | 0.00 | 0.2468 | 0.00 | -- | -- | 0.00 | -186.64 | -111.48 | -527.32 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Renovaro Inc | 0.00 | -115.69m | 79.96m | 25.00 | -- | 0.8096 | -- | -- | -0.9343 | -0.9343 | 0.00 | 0.6223 | 0.00 | -- | -- | 0.00 | -128.97 | -39.86 | -158.19 | -42.11 | -- | -- | -- | -- | -- | -9.65 | 0.0259 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
Data as of Nov 21 2024. Currency figures normalised to Aerovate Therapeutics Inc's reporting currency: US Dollar USD
50.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2024 | 9.19m | 31.84% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.13m | 3.90% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 864.25k | 2.99% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 628.94k | 2.18% |
| Affinity Asset Advisors LLCas of 30 Sep 2024 | 600.00k | 2.08% |
| Eversept Partners LPas of 30 Sep 2024 | 485.14k | 1.68% |
| Octagon Capital Advisors LPas of 30 Sep 2024 | 465.44k | 1.61% |
| Opaleye Management, Inc.as of 30 Sep 2024 | 440.00k | 1.52% |
| GSA Capital Partners LLPas of 30 Sep 2024 | 413.80k | 1.43% |
| Ikarian Capital LLCas of 30 Sep 2024 | 367.97k | 1.28% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
